OP449 inhibits breast cancer growth without adverse metabolic effects.

about

OP449 inhibits breast cancer growth without adverse metabolic effects.

Item

http://www.wikidata.org/entity/Q38613399

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

OP449 inhibits breast cancer growth without adverse metabolic effects.

@en

type

Item

label

OP449 inhibits breast cancer growth without adverse metabolic effects.

@en

prefLabel

OP449 inhibits breast cancer growth without adverse metabolic effects.

@en

P1476

OP449 inhibits breast cancer growth without adverse metabolic effects.

@en

P2093

Aviva Tobin-Hess

http://www.w3.org/2001/XMLSchema#string

Emily Jane Gallagher

http://www.w3.org/2001/XMLSchema#string

Gadi Shlomai

http://www.w3.org/2001/XMLSchema#string

Irini Markella Antoniou

http://www.w3.org/2001/XMLSchema#string

Marilyn Stasinopoulos

http://www.w3.org/2001/XMLSchema#string

Michael P Vitek

http://www.w3.org/2001/XMLSchema#string

Zara Zelenko

http://www.w3.org/2001/XMLSchema#string

P2860

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A

Identification of PP2A complexes and pathways involved in cell transformation

Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene

Diabetes and cancer: a consensus report.

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults

Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia

Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes

Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.

P304

519-529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-17-0077

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Derek LeRoith

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28830934

http://www.w3.org/2001/XMLSchema#string

P932

5678946

http://www.w3.org/2001/XMLSchema#string